The SOLOIST-WHF49 trial investigated combined SGLT2 and SGLT1 inhibition via sotagliflozin in recently worsening HFpEF with T2DM, although the trial was terminated early following the COVID-19 pandemic and insufficient funding. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.